Bendano et al. reported the results of a phase 2 study that evaluated erlotinib, which is an EGFR TKI, and bevacizumab, which is an anti-angiogenesis agent, in patients with recurrent thymoma and thymic carcinoma [15]. The gene discussed is EGFR; the disease is thymoma.